HALOZYME THERAPEUTICS, INC. 4

Bernadette Connaughton sold 1,626 shares of Halozyme Therapeutics, Inc. common stock at $102.80 per share under a Rule 10b5-1 plan.

On August 10, 2026, reporting person Bernadette Connaughton, an insider of Halozyme Therapeutics, Inc., sold 1,626 shares of common stock at a price of $102.80 per share for total proceeds of approximately $167,633 under a Rule 10b5-1 trading plan adopted on May 29, 2025. Following this planned sale, her direct ownership decreased to 40,418 shares of Halozyme common stock, which, using the reported sale price as a proxy for current value, represents an equity stake worth roughly $4.15 million.

Filing Facts

CIK

1159036

Ticker

HALO

Form

4

Source Type

fda

Accession

0001662521-26-000002

Alert Tier

5